| Literature DB >> 32864925 |
Ceyhun Coskun1, Ferhat Borulu2, Izzet Emir3, Muhammed Hanedan4, Ilker Mataraci4.
Abstract
OBJECTIVES: Stroke is an important cause of mortality and morbidity in surgery. In the present study, we examined the cerebral oximetry values of patients with carotid artery stenosis who did not present surgical indications and those who did not present carotid artery stenosis in coronary artery bypass grafting (CABG) surgery by comparing their cerebral oximetry values with cerebrovascular disease (CVD).Entities:
Keywords: Anesthesia; Arterial Pressure; Cardiopulmonary Bypass; Carotid Stenosis; Cerebrovascular Circulation; Coronary Artery Bypass; Patient Discharge
Mesh:
Substances:
Year: 2020 PMID: 32864925 PMCID: PMC7454614 DOI: 10.21470/1678-9741-2019-0050
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Clinical characteristicsof patients.
| Group 1 | Group 2 | |||
|---|---|---|---|---|
| Age (years) | 58±11 | 62.6±9.5 | 0.018 | |
| Size (cm) | 170.75±9.1 | 165.6±10 | 0.099 | |
| Weight (kg) | 80.85±12.44 | 75.15±8.98 | 0.106 | |
| Gender | Female, n (%) | 3 (15%) | 5 (25%) | |
| Male, n (%) | 17 (85%) | 15 (75%) | 0.69 | |
| COPD, n (%) | 2 (10%) | 5 (25%) | 0.212 | |
| CRF, n (%) | 1 (5%) | 0 (0%) | 0.311 | |
| Hypertension, n (%) | 10 (50%) | 15 (75%) | 0.102 | |
| Hyperlipidemia, n (%) | 6 (30%) | 9 (45%) | 0.327 | |
| Diabetes mellitus, n (%) | 5 (25%) | 14 (70%) | 0.004 | |
| Smoke, n (%) | 8 (40%) | 9 (45%) | 0.749 | |
| Old CVE, n (%) | 0 (0%) | 5 (25%) | 0.047 | |
| PAD, n (%) | 0 (0%) | 3 (15%) | 0.072 | |
COPD=chronic obstructive pulmonary disease; CRF=chronic renal failure; CVE=cerebrovascular PAD=peripheral arterial disease
Distribution of patients according to carotid lesions.
| Right | Mildstenosis | 5 (25%) |
| Moderatestenosis | 5 (25%) | |
| Left | Mildstenosis | 2 (10%) |
| Moderatestenosis | 3 (15%) | |
| Bilateral stenosis | 5 (25%) | |
Intraoperative and postoperative early period findings.
| Group 1 | Group 2 | ||
|---|---|---|---|
| Pump time (min.) | 87.25 | 81.85 | 0.550 |
| Cross-clamp time(min.) | 57.70 | 59.20 | 0.801 |
| Intubation time (hours) | 9.41 | 23.33 | 0.234 |
| Lengthof intensive care (days) | 3.25 | 3.85 | 0.407 |
| Hospital stay (days) | 7.95 | 9.50 | 0.185 |
Cerebral oxymetry analysis between groups during different periods.
| Pre-induction | Pump start | After cross-clamping | Pump end | Intensive care unit | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
| |||||||
| CO(right)(%) | Group 1 | 64.15 | 0.321 | 64.7 | 0.235 | 62.35 | 1 | 62.65 | 0.293 | 59.85 | 0.984 |
| Group 2 | 61.85 | 61.4 | 62.35 | 64.85 | 59.9 | ||||||
| CO (left)(%) | Group 1 | 64.65 | 0.252 | 66.7 | 0.131 | 63.3 | 0.577 | 65 | 0.529 | 60.75 | 0.676 |
| Group 2 | 61.45 | 61.05 | 61.55 | 63.3 | 59.65 | ||||||
| Peripheral O2 | Group 1 | 97.05 | 0.578 | 97.95 | 0.394 | 98 | 0.511 | 98.05 | 0.197 | 98.55 | 0.399 |
| Group 2 | 97.7 | 97.1 | 98.45 | 98.8 | 97.8 | ||||||
| MAP (mmHg) | Group 1 | 93.8 | 0.008 | 65.1 | 0.609 | 57.85 | 0.001 | 64.05 | 0.245 | 77.95 | 0.111 |
| Group 2 | 78.1 | 67.1 | 75.85 | 70.45 | 70.35 | ||||||
| Temperature (ºC) | Group 1 | 36.28 | 0.903 | 33.83 | 0.278 | 32.27 | 0.687 | 36.8 | 0.626 | 36.79 | 0.006 |
| Group 2 | 36.26 | 34.42 | 32.5 | 36.65 | 36.49 | ||||||
| pH | Group 1 | 7.42 | 0.51 | 7.41 | 0.941 | 7.42 | 0.119 | 7.36 | 0.199 | 7.36 | 0.012 |
| Group 2 | 7.43 | 7.41 | 7.39 | 7.32 | 7.31 | ||||||
| pCO2 (mmHg) | Group 1 | 35.16 | 0.015 | 37.53 | 0.023 | 36.3 | 0.194 | 40.88 | 0.008 | 41.87 | 0.118 |
| Group 2 | 30.39 | 32.02 | 33.66 | 34.69 | 38.03 | ||||||
| pO2 (mmHg) | Group 1 | 106.44 | 0.087 | 258.7 | 0.385 | 249.2 | 0.045 | 175.24 | 0.605 | 162.9 | 0.547 |
| Group 2 | 138.85 | 234.85 | 291.25 | 192.3 | 175.32 | ||||||
| HCO-3 (mmol/L) | Group 1 | 23.98 | 0.202 | 24.13 | 0.002 | 23.94 | 0.003 | 22.46 | 0.001 | 23.25 | 0.001 |
| Group 2 | 23.05 | 21.23 | 21.52 | 19.08 | 19.67 | ||||||
| BE (mmol/L) | Group 1 | -0.89 | 0.138 | -0.8 | 0.002 | -0.49 | 0.001 | -2.01 | 0.199 | -1.24 | 0.001 |
| Group 2 | -2.27 | -4.1 | -3.81 | -6.55 | -6.54 | ||||||
| Hematocrit (%) | Group 1 | 40.31 | 0.117 | 29.24 | 0.781 | 27.4 | 0.325 | 29.25 | 0.067 | 31.12 | 0.233 |
| Group 2 | 37.31 | 29.69 | 26.33 | 26.85 | 29.65 | ||||||
| Glucose (mg/dL) | Group 1 | 133.4 | 0.299 | 141.25 | 0.028 | 153 | 0.038 | 198.95 | 0.833 | 196.1 | 0.272 |
| Group 2 | 151.5 | 176.6 | 202.95 | 202.95 | 217.55 | ||||||
MAP=mean arterial pressure; CO=cerebral oximetry
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
| ABP | = Arterial blood pressure | Hct | = Hematocrit | |
| BD | = Base deficit | ICU | = Intensive care unit | |
| CABG | = Coronary arterial bypass grafting | CO | = Cardiac output | |
| CBF | = Cerebral blood flow | MAP | = Mean arterial pressure | |
| COPD | = Chronic obstructive pulmonary disease | MRI | = Magnetic resonance imaging | |
| CPB | = Cardiopulmonary bypass | NIRS | = Near-infrared spectroscopy | |
| CPP | = Cerebral perfusion pressure | NSE | = Neuron-specific enolase | |
| CVD | = Cerebrovascular disease | PaO2 | = Partial pressure of arterial oxygen | |
| CVE | = Cerebrovascular event | rSO2 | = Cerebral oxygen saturation | |
| ECG | = Electrocardiography | SEPs | = Somatosensory evoked potentials | |
| EEG | = Electroencephalography | SpO2 | = Peripheral oxygen saturation by pulse oximetry | |
| ETCO2 | = End-tidal carbon dioxide measurement | TCD | = Transcranial Doppler ultrasonography | |
| Authors' roles & responsibilities | |
|---|---|
| CC | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| FB | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| IE | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| MH | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| IM | Final approval of the version to be published |